Information Provided By:
Fly News Breaks for July 24, 2019
SMED
Jul 24, 2019 | 06:09 EDT
Roth Capital analyst Gerry Sweeney started Sharps Compliance with a Buy rating and $4.50 price target. The company is positioned to benefit from market growth and expansion into route-based collections and unused medications, Sweeney tells investors in a research note. He believes Sharps can grow organically at 8%-10% per year.
News For SMED From the Last 2 Days
There are no results for your query SMED